Inventiva is developing lanifibranor, an oral pan-PPAR agonist aimed at treating MASH (metabolic dysfunction-associated steatohepatitis). The drug offers dual metabolic and anti-fibrotic benefits and is seen as complementary to existing treatments like GLP-1 and SGLT2 agents. Inventiva has secured enough funding through mid-2027 and improved governance ahead of the pivotal NATiV3 Phase 3 trial results expected in Q4 2026. Success in this trial could establish lanifibranor as a versatile and differentiated option in the evolving MASH treatment landscape.
Lockheed Martin received a buy rating driven by its record $230 billion backlog and strong growth across multiple business segments, including missile and air defense programs like PAC-3 and THAAD. The F-35 program continues to be a major revenue and...
Vertiv Holdings is positioned as a key player in the growing AI and data center market, which is expected to expand significantly with increasing capital expenditures. Despite the stock doubling in value over the past year, further growth potential r...
The XRP Ledger reached 8 million activated accounts in mid-2026, but daily active addresses have dropped sharply by about 61%, indicating less retail activity. Despite fewer users, average transaction values have soared to around $85,000, surpassing ...
Lighter (LIT) surged 13% to a new local high of $4.67, marking its third consecutive day of gains and outperforming both Hyperliquid (HYPE) and Ethereum (ETH) over the past five months. This rally is driven by increased network activity following the...
Weyerhaeuser's stock has declined about 7% over the past year due to weak demand from a prolonged downturn in the US housing market. Elevated mortgage rates and limited construction capacity continue to suppress lumber demand, delaying recovery likel...
